IKK-ε coordinates invasion and metastasis of ovarian cancer.
about
Transcriptional regulation of chemokine expression in ovarian cancerPre-diagnostic serum levels of inflammation markers and risk of ovarian cancer in the prostate, lung, colorectal and ovarian cancer (PLCO) screening trial.Human monocytes in the presence of interferons alpha2a and gamma are potent killers of serous ovarian cancer cell lines in combination with paclitaxel and carboplatinLoss of compensatory pro-survival and anti-apoptotic modulator, IKKε, sensitizes ovarian cancer cells to CHEK1 loss through an increased level of p21.A TDO2-AhR signaling axis facilitates anoikis resistance and metastasis in triple-negative breast cancer.Epigenetic repression of PDZ-LIM domain-containing protein 2 promotes ovarian cancer via NOS2-derived nitric oxide signaling.Proteasome inhibition increases recruitment of IκB kinase β (IKKβ), S536P-p65, and transcription factor EGR1 to interleukin-8 (IL-8) promoter, resulting in increased IL-8 production in ovarian cancer cells.Risk of ovarian cancer and the NF-κB pathway: genetic association with IL1A and TNFSF10IKKε and TBK1 expression in gastric cancer.The bifacial role of helminths in cancer: involvement of immune and non-immune mechanisms.Therapeutic microRNAs targeting the NF-kappa B signaling circuits of cancers.Characterization of ovarian cancer cell lines as in vivo models for preclinical studies.Biomarker Accessible and Chemically Addressable Mechanistic Subtypes of BRAF Melanoma.NNMT promotes epigenetic remodeling in cancer by creating a metabolic methylation sink.Molecular Pathways: The Balance between Cancer and the Immune System Challenges the Therapeutic Specificity of Targeting Nuclear Factor-κB Signaling for Cancer TreatmentBRD4 facilitates DNA damage response and represses CBX5/Heterochromatin protein 1 (HP1).NFκB Promotes Ovarian Tumorigenesis via Classical Pathways That Support Proliferative Cancer Cells and Alternative Pathways That Support ALDH+ Cancer Stem-like Cells.IΚΚε cooperates with either MEK or non-canonical NF-kB driving growth of triple-negative breast cancer cells in different contexts.Aphthous ulcer drug inhibits prostate tumor metastasis by targeting IKKɛ/TBK1/NF-κB signalingRoles for the IKK-Related Kinases TBK1 and IKKε in Cancer
P2860
Q26825361-3E9F626F-DEA2-4F92-AD8F-90DB58333630Q34624404-164A6412-E3E5-45B5-B7E7-05A265D6BF93Q34920079-8EF07633-DE4E-40EE-8B39-4B8B880B42B7Q35149603-73EE650E-03A3-4358-8208-7EDBED4108E9Q36244860-C9B6E685-2E1F-49A0-BEF6-508A70B81279Q36738846-159F3CEE-EADB-4A22-8B2F-498602DCC12EQ37536497-182E84D7-3D98-4045-8571-685C7EB0520BQ37624504-84891248-39D5-434D-AE3F-A7A9AF79A4CEQ37725411-2CD69F99-5B0D-4479-AC15-FC6A44E4CA49Q38192723-B8C59F5C-836A-46A4-AECC-39E6E480DECBQ38249091-3D769CF2-F937-4178-97C9-A190BBC59235Q38767850-40B3DA94-50F2-4D25-93B0-727416CEC955Q38813507-A2B3BFD5-C3C7-400A-BDD6-AB7BE966584EQ39968449-4A037F38-7707-4E83-B3F0-25FA6B815C99Q40648639-343E2DC2-3D44-422F-AC24-8E5A9EA4E38FQ41612803-C65556D2-C903-48E8-8EB2-42868D0513F6Q47598471-F4621445-B136-4CD8-9ED7-868D4E0397C7Q55247109-62E122CD-00ED-4469-86F3-6FD7A4B27444Q57116175-02B3886E-15F7-4831-85B7-C8345C2EC1C2Q58737053-9CF0EB20-5D2A-41B3-AA8B-1FEEB5FB1F33
P2860
IKK-ε coordinates invasion and metastasis of ovarian cancer.
description
2012 nî lūn-bûn
@nan
2012年の論文
@ja
2012年学术文章
@wuu
2012年学术文章
@zh-cn
2012年学术文章
@zh-hans
2012年学术文章
@zh-my
2012年学术文章
@zh-sg
2012年學術文章
@yue
2012年學術文章
@zh
2012年學術文章
@zh-hant
name
IKK-ε coordinates invasion and metastasis of ovarian cancer.
@ast
IKK-ε coordinates invasion and metastasis of ovarian cancer.
@en
type
label
IKK-ε coordinates invasion and metastasis of ovarian cancer.
@ast
IKK-ε coordinates invasion and metastasis of ovarian cancer.
@en
prefLabel
IKK-ε coordinates invasion and metastasis of ovarian cancer.
@ast
IKK-ε coordinates invasion and metastasis of ovarian cancer.
@en
P2093
P2860
P1433
P1476
IKK-ε coordinates invasion and metastasis of ovarian cancer
@en
P2093
Ben Davidson
Christina M Annunziata
Lidia Hernandez
Marianne Kim
Miriam Anver
Valentina Grajales
P2860
P304
P356
10.1158/0008-5472.CAN-11-3993
P407
P577
2012-08-31T00:00:00Z